EVLO Evelo Biosciences, Inc. Stock Quote

EVLO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.31	Insider Own	0.20%	Shs Outstand	53.53M	Perf Week	-10.63%
Market Cap	112.46M	Forward P/E	-	EPS next Y	-1.45	Insider Trans	0.00%	Shs Float	50.49M	Perf Month	-19.57%
Income	-122.20M	PEG	-	EPS next Q	-0.55	Inst Own	94.20%	Short Float	16.61%	Perf Quarter	-53.75%
Sales	-	P/S	-	EPS this Y	2.70%	Inst Trans	0.07%	Short Ratio	26.92	Perf Half Y	-82.48%
Book/sh	0.16	P/B	11.56	EPS next Y	4.60%	ROA	-97.60%	Target Price	17.75	Perf Year	-83.35%
Cash/sh	1.13	P/C	1.64	EPS next 5Y	-	ROE	-255.80%	52W Range	1.60 - 17.12	Perf YTD	-69.52%
Dividend	-	P/FCF	-	EPS past 5Y	-37.50%	ROI	-	52W High	-89.02%	Beta	1.82
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	-	Gross Margin	-	52W Low	17.87%	ATR	0.30
Employees	122	Current Ratio	4.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.67	Volatility	17.33% 14.45%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	13.80%	Profit Margin	-	Rel Volume	1.10	Prev Close	1.85
Shortable	Yes	LT Debt/Eq	5.36	Earnings	Mar 24 BMO	Payout	-	Avg Volume	311.59K	Price	1.88
Recom	2.00	SMA20	-17.41%	SMA50	-33.12%	SMA200	-70.01%	Volume	42,028	Change	1.62%

Nov-01-21

Upgrade

Chardan Capital Markets

Neutral → Buy

$12

Jun-23-21

Initiated

Cantor Fitzgerald

Overweight

$28

Apr-12-21

Upgrade

Jefferies

Hold → Buy

$11 → $18

Dec-23-20

Initiated

JMP Securities

Mkt Outperform

$27

May-21-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

May-12-20

Downgrade

Jefferies

Buy → Hold

$18 → $6

Apr-30-19

Initiated

Jefferies

Buy

$18

Jan-29-19

Initiated

Chardan Capital Markets

Neutral

$10

May-12-22 10:47AM	CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights GlobeNewswire -9.66%
06:00AM	Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights GlobeNewswire
Apr-21-22 06:00AM	Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors GlobeNewswire
Apr-14-22 11:22AM	Read Why Did Evelo Discontinue EDP1867 Atopic Dermatitis Program Benzinga
06:00AM	Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs GlobeNewswire
Apr-06-22 06:00AM	Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors GlobeNewswire
Mar-26-22 12:00PM	Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting GlobeNewswire
Mar-24-22 01:30PM	Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript Motley Fool +25.99%
12:40PM	Evelo Biosciences Shares Gain After Positive Data On Faster Release EDP1815 Capsule, Q4 Earnings Benzinga
06:00AM	Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Mar-17-22 07:00AM	Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022 GlobeNewswire
Mar-07-22 06:00AM	Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines GlobeNewswire
Mar-02-22 08:50AM	Why Evelo Biosciences (EVLO) Might Surprise This Earnings Season Zacks
07:00AM	Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference GlobeNewswire
Feb-28-22 09:00AM	Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire -8.36%
06:00AM	Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Biosciences Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis GlobeNewswire
Feb-24-22 07:55AM	5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates Zacks +15.95%
Feb-17-22 07:00AM	Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis GlobeNewswire -9.25%
Feb-15-22 10:05AM	INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT PR Newswire
Feb-11-22 12:00PM	Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know Zacks -5.80%
Feb-07-22 07:00AM	Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial GlobeNewswire
Jan-17-22 07:00AM	Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases GlobeNewswire
Jan-04-22 07:00AM	Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts GlobeNewswire
Dec-14-21 07:00AM	Evelo Biosciences Added to Nasdaq Biotechnology Index GlobeNewswire -8.21%
Nov-09-21 07:00AM	Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference GlobeNewswire
Oct-28-21 07:01PM	Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript Motley Fool
07:00AM	Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Oct-21-21 07:00AM	Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021 GlobeNewswire
Oct-18-21 08:49AM	How Many Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares Do Institutions Own? Simply Wall St.
Oct-13-21 10:47AM	Wall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade Zacks -9.32%
10:00AM	Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change PR Newswire
07:00AM	Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) GlobeNewswire
Sep-29-21 03:37AM	48 Biggest Movers From Yesterday Benzinga -9.16%
Sep-28-21 12:38PM	36 Stocks Moving In Tuesday's Mid-Day Session Benzinga +7.41%
12:31PM	Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study Zacks
Sep-27-21 12:11PM	Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide Benzinga
07:40AM	Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study Benzinga
02:00AM	Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX, to Treat Systemic Inflammatory Disease GlobeNewswire
Sep-20-21 07:00AM	Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference GlobeNewswire -13.79%
04:58AM	48 Biggest Movers From Friday Benzinga
Sep-09-21 07:00AM	Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines GlobeNewswire
Sep-08-21 08:30AM	Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options Zacks
Sep-07-21 07:00AM	Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors GlobeNewswire
Aug-06-21 08:46AM	Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock? Zacks
Jul-31-21 05:31AM	Evelo Biosciences, Inc. (EVLO) Q2 2021 Earnings Call Transcript Motley Fool
Jul-29-21 07:00AM	Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire +8.83%
Jul-22-21 07:00AM	Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021 GlobeNewswire -22.71%
Jul-14-21 04:01PM	Evelo Biosciences Announces Grant of Inducement Award GlobeNewswire -8.75%
Jun-21-21 06:50PM	Should I Buy Evelo Biosciences, Inc. (EVLO)? Insider Monkey
Jun-16-21 04:01PM	Evelo Biosciences Announces Grant of Inducement Award GlobeNewswire
Jun-03-21 04:01PM	Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team GlobeNewswire
Jun-01-21 07:00AM	Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer GlobeNewswire +6.11%
May-26-21 07:00AM	Evelo Biosciences to Present at Upcoming Investor Conferences in June GlobeNewswire
May-25-21 06:00AM	Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire +6.28%
May-19-21 09:01AM	Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire -6.72%
May-13-21 07:00AM	Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting GlobeNewswire +8.15%
Apr-30-21 03:59PM	Drugs from bugs biotech companies are mining the gut microbiome to treat difficult diseases MarketWatch +7.43%
Apr-29-21 03:01PM	Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript Motley Fool
07:00AM	Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights GlobeNewswire
06:30AM	Evelo Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Apr-22-21 07:00AM	Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021 GlobeNewswire -5.34%
Apr-20-21 04:01PM	Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis GlobeNewswire -6.15%
Apr-19-21 05:50AM	Are Institutions Heavily Invested In Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Shares? Simply Wall St.
Apr-15-21 07:00AM	Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors GlobeNewswire
Apr-05-21 07:00AM	Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-30-21 09:30AM	Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire
Mar-23-21 03:00AM	Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People GlobeNewswire -6.14%
Mar-09-21 05:00PM	Evelo Biosciences, Inc. (EVLO) Q4 2020 Earnings Call Transcript Motley Fool +11.05%
07:00AM	Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights GlobeNewswire
05:30AM	Evelo Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-21 07:00AM	Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021 GlobeNewswire
Feb-16-21 07:00AM	Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors GlobeNewswire
Jan-28-21 09:08PM	Evelo Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire +11.71%
04:01PM	Evelo Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-21-21 08:05AM	The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga -7.03%
Jan-20-21 07:00AM	Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis GlobeNewswire
Jan-07-21 07:00AM	Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones GlobeNewswire +5.34%
Dec-23-20 10:07AM	Benzinga's Top Upgrades, Downgrades For December 23, 2020 Benzinga
Dec-21-20 07:00AM	Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer GlobeNewswire
Dec-14-20 11:21PM	Insider Buying: The Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman Just Bought 77% More Shares Simply Wall St. +24.80%
Dec-09-20 09:00AM	Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer GlobeNewswire +22.33%
07:00AM	Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis GlobeNewswire
Dec-03-20 07:00AM	Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis GlobeNewswire
Nov-27-20 10:47AM	Hedge Funds Are Dumping Evelo Biosciences, Inc. (EVLO) Insider Monkey
Nov-10-20 09:41AM	What You Need To Know About Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Investor Composition Simply Wall St.
Nov-09-20 08:00AM	Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting GlobeNewswire +7.32%
Oct-29-20 07:00AM	Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
06:30AM	Evelo Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-22-20 04:01PM	Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020 GlobeNewswire
Oct-15-20 07:00AM	Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815 GlobeNewswire -7.89%
Oct-14-20 07:00AM	Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis GlobeNewswire
Oct-13-20 07:00AM	Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis GlobeNewswire
Oct-12-20 09:00AM	Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session Zacks
Sep-14-20 07:06AM	Evelo Biosciences Appoints Julie Carretero as Chief People Officer GlobeNewswire +10.45%
Sep-08-20 07:00AM	Evelo Biosciences to Participate in Upcoming Investor Conferences in September GlobeNewswire +6.95%
Jul-30-20 07:00AM	Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Jul-23-20 07:00AM	Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020 GlobeNewswire -6.31%
Jul-07-20 08:00AM	Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing PR Newswire
Jul-01-20 07:08AM	Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting GlobeNewswire
Jun-24-20 07:56PM	Evelo Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	Director	May 02	Option Exercise	0.00	4,926	0	66,957	May 02 04:03 PM
Epstein David R	Director	Mar 31	Option Exercise	0.00	4,926	0	62,031	Apr 01 04:05 PM
Epstein David R	Director	Feb 28	Option Exercise	0.00	4,926	0	57,105	Mar 01 04:07 PM
Epstein David R	Director	Jan 31	Option Exercise	0.00	4,925	0	52,179	Jan 31 05:06 PM
Epstein David R	Director	Dec 31	Option Exercise	0.00	4,926	0	47,254	Jan 03 04:23 PM
Epstein David R	Director	Nov 30	Option Exercise	0.00	4,926	0	42,328	Dec 01 04:39 PM
Epstein David R	Director	Nov 01	Option Exercise	0.00	4,925	0	37,402	Nov 01 05:22 PM
Epstein David R	Director	Oct 01	Option Exercise	0.00	4,927	0	32,477	Oct 01 04:42 PM
Epstein David R	Director	Sep 03	Option Exercise	0.00	9,850	0	27,550	Sep 03 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience